title: Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs.
abstract: Balloon angioplasty has become an important intervention in clinical cardiology; however, the technique is associated with a high incidence of restenosis, requiring repeated procedures. Endothelin-1 (ET-1), specifically through its action on ET(A) receptors, has been implicated in the cell proliferation and subsequent neointimal formation that leads to restenosis. Therefore we examined a potent antagonist of the ET(A) receptor, A127722.5, in a pig model of balloon angioplasty in iliac and carotid arteries. Ten pigs received A-127722.5 (7.5 mg/kg b.i.d.) orally, starting 3 days before angioplasty and continuing for 4 weeks; 10 additional pigs were treated with the same dosing regimen of the angiotensin-converting enzyme (ACE) inhibitor captopril (3.0 mg/kg b.i.d.), while a third group of 10 animals received placebo. At 2 and 4 weeks after the start of treatment, these doses of the ET(A) receptor antagonist and ACE inhibitor blocked the presser responses induced by big ET-1 and angiotensin I, respectively. In the iliac arteries, neointimal formation, neointimal/medial ratio, and maximal neointimal thickness were all significantly reduced, and the residual lumen area was significantly increased in pigs treated with the ET(A) receptor antagonist compared with placebo and captopril-treated groups. Medial collagen content, collagen deposition, and medial growth also were significantly reduced relative to the placebo group. Beneficial effects also were observed in the carotid arteries, although the results were less striking. Captopril was ineffective in protecting against the effects of balloon angioplasty in both vessels. Our results indicate that an orally active and potent antagonist of the ET(A) receptor inhibits cell proliferation and synthesis of extracellular matrix in pigs and may provide an important therapeutic approach to the prevention of restenosis.
authors.affiliation: Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064-3500, U.S.A.
authors.forename: S E
authors.initials: SE
authors.lastname: Burke
authors.forename: N L
authors.initials: NL
authors.lastname: Lubbers
authors.forename: G D
authors.initials: GD
authors.lastname: Gagne
authors.forename: J L
authors.initials: JL
authors.lastname: Wessale
authors.forename: B D
authors.initials: BD
authors.lastname: Dayton
authors.forename: C D
authors.initials: CD
authors.lastname: Wegner
authors.forename: T J
authors.initials: TJ
authors.lastname: Opgenorth
mesh_terms: D000800:Angioplasty, Balloon / Q000009:adverse effects*; D000803:Angiotensin I / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000077868:Atrasentan; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology; D020212:Carotid Artery Injuries; D017536:Carotid Artery, Common / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D003094:Collagen / Q000096:biosynthesis; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000097:blood / Q000494:pharmacology; D006965:Hyperplasia; D007083:Iliac Artery / Q000187:drug effects / Q000293:injuries / Q000378:metabolism / Q000473:pathology; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000293:injuries / Q000378:metabolism / Q000473:pathology; D011759:Pyrrolidines / Q000097:blood / Q000494:pharmacology*; D044022:Receptor, Endothelin A; D013552:Swine; D013556:Swine, Miniature; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D011759:Pyrrolidines; D044022:Receptor, Endothelin A; D003094:Collagen; D000803:Angiotensin I; D002216:Captopril; D000077868:Atrasentan